.Discuss the pathophysiology and diagnosis of a case of pheochromocytoma. Give an account of preparation monitoring and anesthetic management of a 25 years old patient suffering from pheochromocytoma. For MD anaesthesia exam

Reading File

Now let me search the medical library in parallel across all relevant topics for this comprehensive MD exam question.

Finding Sources

Searching PubMed

pheochromocytoma anesthetic management perioperative

Miller's Anesthesia has the most relevant content. Let me read those blocks in parallel along with surgical and pharmacology content.

Reading File

Finding Sources

Excellent content found. Let me now read the Miller's Anesthesia pheochromocytoma section more fully and the Morgan & Mikhail block in parallel.

Reading File

Excellent. Now let me read the Miller's Anesthesia pheochromocytoma intraoperative section and also get the Morgan & Mikhail Case Discussion section which was referenced.

Reading File

Finding Sources

I now have excellent, comprehensive data from Miller's Anesthesia, Morgan & Mikhail, and Fischer's Surgery. Let me compile this into a thorough MD exam answer.---

Pheochromocytoma: Pathophysiology, Diagnosis, and Anesthetic Management

MD Anaesthesia Examination Answer

1. DEFINITION AND OVERVIEW

Pheochromocytomas and paragangliomas (PPGLs) are catecholamine-producing tumors derived from chromaffin tissue of the adrenal medulla and sympathetic chain ganglia, respectively. Pheochromocytoma specifically refers to the adrenal form; extra-adrenal variants are called paragangliomas.

The "10% Rule" (Rule of 10s):

~10% are malignant (metastatic) - though recent evidence suggests all carry malignant potential
10% are bilateral
10% are extra-adrenal (paragangliomas)
10% occur in children
10% are familial

They account for 0.1% of all causes of hypertension. Historically, perioperative mortality was 25%-50%; with modern management it has fallen dramatically.

Associated syndromes:

Multiple Endocrine Neoplasia (MEN) type IIa and IIb
Von Hippel-Lindau disease
Neurofibromatosis type I
Succinate dehydrogenase (SDH) mutations

2. PATHOPHYSIOLOGY

Tumor Origin and Catecholamine Synthesis

Pheochromocytoma cells are modified postganglionic sympathetic neurons. They synthesize, store, and release catecholamines - epinephrine (Epi), norepinephrine (NE), and dopamine - in an unregulated fashion.

The synthetic pathway:

Tyrosine → DOPA → Dopamine → Norepinephrine → Epinephrine

(via tyrosine hydroxylase, DOPA decarboxylase, dopamine β-hydroxylase, and PNMT)

Catecholamines are metabolized to metanephrine and normetanephrine (collectively "metanephrines") and then to vanillylmandelic acid (VMA).

Cardiovascular Pathophysiology

Alpha (α1/α2) receptor stimulation:

Intense peripheral vasoconstriction → paroxysmal or sustained hypertension
Reduced plasma volume (chronic vasoconstriction reduces capacitance)
Reflex bradycardia (at times)

Beta (β1/β2) receptor stimulation:

Positive inotropy and chronotropy → tachycardia, palpitations
Increased cardiac output
Arrhythmias (including ventricular ectopy)

Catecholamine cardiomyopathy:

Sustained catecholamine excess causes direct myocardial toxicity
Results in dilated or takotsubo-like cardiomyopathy
Coronary vasospasm can produce myocardial ischemia even with normal coronaries

Metabolic Effects

Hyperglycemia: Beta-receptor stimulation promotes gluconeogenesis; alpha-2 stimulation inhibits insulin release
Increased BMR: Weight loss, heat intolerance, diaphoresis
Hypovolemia: Chronic vasoconstriction contracts plasma volume; hematocrit may be paradoxically elevated

Hemodynamic Instability Mechanism

During surgery, two critical phases exist:

Tumor manipulation - massive catecholamine surge → hypertensive crisis, arrhythmias
After adrenal vein ligation - abrupt catecholamine withdrawal + persisting adrenergic blockade + hypovolemia → profound hypotension

3. CLINICAL FEATURES

Classic Triad (Menniger's Triad)

Episodic headache (throbbing, severe)
Diaphoresis (profuse sweating)
Palpitations/tachycardia

This triad has ~90% sensitivity for pheochromocytoma.

Other Features

Paroxysmal or sustained hypertension (may be refractory to multiple agents)
Anxiety, panic attacks, tremors
Pallor (NE-mediated vasoconstriction) or flushing (epinephrine-predominant tumors)
Weight loss, nausea, vomiting
Chest pain, dyspnea
Hypertensive encephalopathy, retinopathy

Triggers of Paroxysms

Positional changes (tumor compression)
Exercise, emotional stress, anxiety
Drugs: beta-blockers without prior alpha-blockade, histamine-releasing drugs (morphine, atracurium), glucagon, metoclopramide, tricyclics, tyramine-containing foods, contrast dye
Induction of anesthesia, endotracheal intubation
Abdominal palpation

In a 25-Year-Old Patient

Young age is a red flag. The 2014 Endocrine Society guidelines emphasize that pheochromocytoma should be suspected in any young (especially <20 years old) hypertensive patient or in patients with hypertension not responding to standard therapy. Genetic testing is strongly recommended as up to 40% of younger patients have an identifiable germline mutation.

4. DIAGNOSIS

Step 1 - Biochemical Diagnosis

Preferred initial tests:

Test	Sensitivity	Specificity	Notes
Plasma fractionated metanephrines	96-100%	85-89%	Best when high index of suspicion (adrenal mass, familial syndrome)
24-hr urine fractionated metanephrines + catecholamines	>98%	>98%	Best when low index of suspicion (uncontrolled HTN)
24-hr urine VMA	77%	86%	Older, less sensitive - use alongside metanephrines

Diagnostic threshold: Plasma or urine free metanephrine concentrations more than 2x the upper limit of normal are diagnostic.

If borderline elevated: Clonidine suppression test - clonidine suppresses neurogenic catecholamine release but not tumor-derived release; failure to suppress plasma NE by >50% indicates pheochromocytoma.

Important note: Beta-blockers, labetalol, tricyclics, and certain foods can cause false positives. Collect plasma samples after 30 minutes of supine rest in a quiet environment.

Step 2 - Imaging/Localization

Once biochemistry confirms the diagnosis:

CT abdomen/pelvis - first choice; sensitivity ~98% for adrenal tumors; pheochromocytoma has characteristic "salt and pepper" appearance on T2-weighted MRI
MRI - preferred for extra-adrenal, recurrent, or in young patients (avoids radiation); appears bright on T2-weighted sequences
MIBG scintigraphy (I-131 or I-123 metaiodobenzylguanidine) - functional imaging; taken up by chromaffin tissue; essential for localizing extra-adrenal, multiple, or metastatic tumors
FDG-PET/CT or DOTATATE-PET - used for MIBG-negative or metastatic disease

Step 3 - ECG and Echocardiography

ECG: Look for LVH, ST-T changes, arrhythmias
Echo: Assess for catecholamine cardiomyopathy, LVEF before surgery

Step 4 - Genetic Testing

Genetic testing (SDHB, SDHD, VHL, RET, NF1) should be offered to all young patients with pheochromocytoma.

5. PREOPERATIVE PREPARATION

Surgical resection is the only definitive cure. Preoperative preparation is critical and begins at least 1-2 weeks before surgery (longer if severe hypertension or end-organ damage exists).

Goals of Preoperative Preparation (Roizen Criteria - Modified)

Per the 2014 Endocrine Society Guidelines (preferred over the older Roizen criteria):

Blood pressure target: <130/80 mmHg sitting; systolic >90 mmHg standing
Heart rate: 60-70 bpm sitting; 70-80 bpm standing
ECG: No ST-T changes (stable for 1 week)
Ventricular ectopy: <1 PVC per 5 minutes

Step 1 - Alpha-Adrenergic Blockade (First and Mandatory)

Phenoxybenzamine (PBZ) - Gold Standard:

Non-selective, irreversible (non-competitive) alpha-1 and alpha-2 blocker
Starting dose: 10 mg orally twice daily, titrated by 10-20 mg every 2-3 days
Target dose: 20-100 mg/day based on blood pressure response
Causes orthostatic hypotension (desired - indicates adequate blockade)
Side effects: nasal congestion, reflex tachycardia, fatigue
Duration of action 24-48 hours - advantage is that new tumor-released catecholamines cannot displace it from receptors

Alternative selective alpha-1 blockers:

Doxazosin: 2-16 mg/day - increasingly used due to phenoxybenzamine's cost and availability issues; competitive blocker, can still be displaced during catecholamine surges
Prazosin: 2-5 mg 2-3 times/day
Terazosin: similar

Calcium channel blockers (nicardipine, amlodipine):

Used as adjuncts or in patients without hypertension (systolic BP <120 mmHg) or with normotensive pheochromocytoma
Do not cause reflex tachycardia
Useful for patients who cannot tolerate alpha-blockade side effects

Metyrosine (alpha-methyl-L-tyrosine):

Tyrosine hydroxylase inhibitor - reduces catecholamine synthesis by 50-80%
Reserved for severe, refractory cases or large tumors where standard blockade is insufficient
Expensive, slow onset, not commonly stocked - not routine

CRITICAL WARNING: Never start beta-blockade before establishing adequate alpha-blockade. Unopposed alpha stimulation after beta-blockade leads to hypertensive crisis (loss of beta-mediated vasodilation unmasks alpha-vasoconstriction).

Step 2 - Beta-Adrenergic Blockade (Only After Alpha Blockade)

Indicated for:

Tachycardia (HR >100 bpm)
Tachyarrhythmias
Tumor with predominantly epinephrine secretion

Agents: Propranolol 10-40 mg TID-QID; atenolol; metoprolol

Start only after alpha-blockade is well established (3-4 days minimum)
Continue through the morning of surgery

Step 3 - Volume Expansion

Alpha-blockade causes vasodilation and unmasking of contracted plasma volume
Encourage liberal salt and fluid intake (2-3 L/day of IV saline in hospital, or dietary salt liberalization outpatient)
Hematocrit should fall as volume is restored (if it doesn't, consider inadequate blockade)
Target: euvolemia before surgery; prevents post-tumor-removal hypotension

Step 4 - Additional Optimization

Hyperglycemia: Manage with insulin if required
Catecholamine cardiomyopathy: Optimize cardiac function; may require 4-6 weeks of pretreatment and delay of surgery
ECHO before surgery to assess LVEF
Avoid drugs that trigger catecholamine release: Metoclopramide, opioids (morphine, especially), glucagon

6. PREOPERATIVE MONITORING SETUP

On the morning of surgery, before induction:

Monitor	Rationale
Invasive arterial line (radial artery)	Beat-to-beat BP monitoring; essential due to rapid BP swings during intubation and tumor manipulation
Large-bore IV access (x2)	For rapid volume infusion and vasoactive drugs
Central venous catheter	CVP monitoring; convenient route for vasoactive infusions; post-ligation vasopressors
SpO2, ETCO2	Standard; hypoventilation (hypercarbia) increases catecholamine release
ECG (5-lead)	Continuous arrhythmia monitoring; ST segment analysis
Urinary catheter	Hourly urine output monitoring
Temperature	Avoid hyperthermia (mimics MH)
TEE/TTE (optional)	For patients with suspected cardiomyopathy; assesses volume status and cardiac function intraoperatively
Pulmonary artery catheter	Only in severe cardiac dysfunction

The arterial line must be placed and functional BEFORE induction.

7. ANESTHETIC MANAGEMENT

Premedication

Benzodiazepine (lorazepam 1-2 mg oral, or midazolam 1-2 mg IV) - reduces anxiety-related catecholamine release; given night before and morning of surgery
Continue all antihypertensive medications on the morning of surgery
Avoid anticholinergics (atropine causes tachycardia)
Avoid opioids that release histamine (morphine, codeine) for premedication

Induction of Anesthesia

Goals: Smooth induction with minimal sympathetic stimulation; avoid tachycardia and hypertension during laryngoscopy.

Induction agents:

Propofol (1.5-2.5 mg/kg IV) - preferred; reduces sympathetic tone, minimal effect on catecholamine release
Thiopentone - acceptable alternative
Ketamine - AVOIDED (stimulates sympathetic nervous system, releases catecholamines)

Opioids for blunting intubation response:

Fentanyl 2-5 mcg/kg - given 3-4 min before laryngoscopy
Remifentanil infusion - excellent control during intubation
Alfentanil - also used
Avoid morphine (histamine release)

Intubation:

Do NOT attempt intubation until deep anesthesia is established
Consider lidocaine (1-1.5 mg/kg IV) 90 seconds before laryngoscopy to blunt the pressor response
Topical lignocaine spray to the larynx and trachea is beneficial
Use video laryngoscopy to minimize airway manipulation time

Muscle relaxants:

Vecuronium, rocuronium, or cisatracurium - preferred (no histamine release, no autonomic effects)
Avoid atracurium (large doses cause histamine release) and succinylcholine (causes fasciculations that can squeeze the tumor and release catecholamines; also causes tachycardia)
Avoid pancuronium (vagolytic, increases heart rate)

Maintenance of Anesthesia

Volatile agents:

Isoflurane, sevoflurane, or desflurane - all acceptable
Avoid halothane - sensitizes myocardium to catecholamine-induced arrhythmias (ventricular fibrillation risk)
Maintain adequate depth to suppress sympathetic responses; light anesthesia is a major trigger for hypertensive crises

Total Intravenous Anesthesia (TIVA):

Propofol + remifentanil infusion - excellent, provides titratable anesthesia with minimal catecholamine stimulation

Regional anesthesia adjunct:

Epidural analgesia may be added for postoperative pain control
Does NOT reliably prevent intraoperative hypertensive episodes
Can worsen postoperative hypotension due to sympathectomy effect - use with caution

Ventilation:

Maintain normocarbia (ETCO2 35-40 mmHg); hypercarbia increases sympathetic drive
Avoid large tidal volumes that cause stimulation

Drugs to AVOID:

Drug	Reason
Ketamine	Sympathomimetic, releases catecholamines
Halothane	Sensitizes myocardium to arrhythmias
Succinylcholine	Fasciculations squeeze tumor; autonomic stimulation
Pancuronium	Vagolytic, tachycardia
Morphine / Atracurium (large doses)	Histamine release
Ephedrine	Indirect sympathomimetic, worsens hypertension
Droperidol	Dopamine antagonism can trigger release
Metoclopramide	Triggers catecholamine release
Glucagon	Stimulates catecholamine release

Intraoperative Hypertension Management

When blood pressure rises during tumor manipulation:

First line:

Phentolamine (IV bolus 2-5 mg, repeat as needed) - non-selective alpha-blocker; blocks effects of circulating catecholamines; onset 1-2 min
Nicardipine (0.5-5 mcg/kg/min infusion) or clevidipine - calcium channel blockers, increasingly used as first-line or alongside phentolamine
Sodium nitroprusside (0.5-8 mcg/kg/min) - rapid onset, ultra-short duration; excellent for acute crisis; risk of cyanide toxicity with prolonged use

For tachyarrhythmias:

Esmolol (IV bolus 0.5-1 mg/kg, then 50-300 mcg/kg/min) - short-acting beta-1 blocker; first choice for arrhythmias
Lidocaine for ventricular arrhythmias
Magnesium sulfate - useful for pheochromocytoma-related arrhythmias and catecholamine-induced vasospasm

Post-Ligation Hypotension Management (Critical Phase)

After the adrenal vein is ligated (or main venous drainage is clipped):

Sudden catecholamine withdrawal
Persisting alpha-blockade
Pre-existing hypovolemia

Management:

Aggressive fluid resuscitation - crystalloids (NS, LR) or colloids; guided by CVP, echocardiography
Vasopressors:
- Phenylephrine (100-200 mcg boluses or infusion) - direct alpha-1 agonist; preferred since it does not increase heart rate
- Norepinephrine infusion - for refractory hypotension
- Vasopressin - useful in catecholamine-resistant vasodilatory shock
Correction of hypovolemia takes priority; vasopressors should be viewed as a bridge

Post-ligation hypoglycemia: With tumor removal, the inhibitory effect on insulin secretion is removed; blood glucose should be monitored every 30-60 minutes; IV dextrose infusion may be required.

8. POSTOPERATIVE CARE

Immediate Postoperative Monitoring (ICU/HDU)

Invasive monitoring continued for at least 24-48 hours
Blood pressure: Target normotension; may remain labile for 24-48 hours
Blood glucose: Hypoglycemia is common in the first 24-48 hours; monitor hourly and administer dextrose infusions

Possible Complications

Complication	Cause	Management
Hypotension	Catecholamine withdrawal + adrenergic blockade + hypovolemia	IV fluids + vasopressors
Hypoglycemia	Rebound hyperinsulinism	5-10% dextrose infusion
Persistent hypertension	Residual tumor / incomplete resection / essential HTN	Antihypertensives
Adrenal insufficiency	Bilateral resection or contralateral adrenal suppression	Hydrocortisone replacement
Arrhythmias	Myocardial catecholamine toxicity	Beta-blockers, lidocaine
Pulmonary edema	Catecholamine cardiomyopathy	Diuresis, afterload reduction

Follow-Up

Biochemical testing at 2-4 weeks post-op to confirm cure (plasma/urine metanephrines)
Annual biochemical screening lifelong (recurrence rate ~15%)
Genetic counseling and family screening

9. SUMMARY TABLE: KEY ANESTHETIC DRUGS

Phase	Drug	Role
Preop	Phenoxybenzamine	Alpha-blockade
Preop	Propranolol/esmolol	Beta-blockade (after alpha)
Preop	Nicardipine	CCB adjunct
Premedication	Midazolam	Anxiolysis
Induction	Propofol + fentanyl	Smooth, sympathetically quiet induction
Intubation	Lidocaine IV/topical	Blunt laryngoscopy response
NMBA	Vecuronium/rocuronium	No histamine, no autonomic effects
Maintenance	Isoflurane/sevoflurane	Volatile, adequate depth
HTN crisis	Phentolamine / SNP / nicardipine	Acute BP control
Tachyarrhythmia	Esmolol	Rate control
Post-ligation	Phenylephrine + fluids	Treat hypotension
Postop	Dextrose infusion	Prevent hypoglycemia

SOURCES

Miller's Anesthesia, 10th Edition (Elsevier, 2023) - Pheochromocytoma section, pp. 4239-4243
Morgan & Mikhail's Clinical Anesthesiology, 7th Edition - Catecholamine Excess and Anesthetic Considerations, p. 1432
Fischer's Mastery of Surgery, 8th Edition - Pheochromocytoma, pp. 1337-1338
Recent review: Li YH & Shen L, "Anesthesia Management in Hereditary Pheochromocytoma and Paraganglioma," Chin Med Sci J (2024) [PMID: 39462773]
Gombert AJ et al., "Perioperative Biochemical and Clinical Considerations of Pheochromocytoma Management," Int J Mol Sci (2025) [PMID: 40649858]

---This is a complete MD Anaesthesia examination-level answer. Here is a brief orientation of the key sections:

What this answer covers (exam blueprint):

Pathophysiology - Catecholamine synthesis pathway, cardiovascular and metabolic effects, mechanism of intraoperative hemodynamic instability (hypertension during manipulation vs. hypotension after ligation)
Diagnosis - Biochemical workup (plasma fractionated metanephrines as gold standard, 24-hr urine, clonidine suppression test) followed by imaging (CT, MRI, MIBG scan)
Preoperative Preparation - The mandatory sequence: alpha-blockade FIRST (phenoxybenzamine), then beta-blockade, then volume expansion; the 2014 Endocrine Society BP/HR targets; the Roizen criteria; metyrosine for refractory cases
Monitoring - Arterial line before induction is non-negotiable; central line, 5-lead ECG, urinary catheter, and optional TEE
Anesthetic Management - Drugs to use (propofol, fentanyl, vecuronium, isoflurane) vs. drugs to avoid (ketamine, halothane, succinylcholine, morphine, pancuronium, ephedrine); intraoperative hypertension treatment (phentolamine, nicardipine, SNP); post-ligation hypotension (fluids + phenylephrine); postoperative hypoglycemia

High-yield exam points for a 25-year-old patient: Young age mandates genetic testing; higher likelihood of a familial syndrome (MEN2, VHL, SDH mutation); all the same anesthetic principles apply with heightened vigilance for bilateral disease and lifelong surveillance.

This is a shared conversation. Sign in to Orris to start your own chat.